Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 2 Results

Intervention Indication Therapeutic Area Year Actions
Pembrolizumab in addition to trastuzumab and chemotherapy for HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma – First-line Pembrolizumab (Keytruda; MK-3475) , Trastuzumab (Herceptin; RG-597) Gastric cancer , Gastro-oesophageal junction cancer Gastrointestinal Cancer 2019 View  |  Download
Tucatinib in addition to trastuzumab and capecitabine for advanced breast cancer Capecitabine (Xeloda) , Trastuzumab (Herceptin; RG-597) , Tucatinib (ONT-380) Breast cancer Breast Cancer 2020 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications